(VIANEWS) – Over the past ten sessions, shares of GENOMIC VISION (CAC 40: GV.PA) experienced an unprecedented surge of 21.95%, beginning from EUR0.01 and reaching EUR0.00 at 16:07 EST on Monday afternoon. Following two consecutive gains for CAC 40 index as a whole and 92.73% below its 52-week high of EUR0.11, shares of GENOMIC VISION reached their most recent close at EUR0.00 on Tuesday afternoon.
About GENOMIC VISION
Genomic Vision is a molecular diagnostics and technology company offering single DNA detection tools for use in research studies as well as in vitro diagnostic tests in France. FiberVision, FiberComb, FiberStudio software and accessories make up their range of molecular combing products. FiberProbes for BRCA, as well as Genomic Morse Codes to detect mutations, are provided. The latter enable early diagnosis of hereditary breast and ovarian cancer and hereditary nonpolyposis colorectal cancer. Genomic Vision offers combing services to validate planned gene editing events, detect incorrect events larger than 1kb and quantify off-target/on-target ratios. They have strategic alliances with Quest Diagnostics and La Timone Hospital as well as research agreements with Institut Pasteur; established in 2004 they are headquartered in Bagneux France.
Yearly Analysis
Based on GENOMIC VISION’s current stock price of EUR0.01 and 52-week high and low values of EUR0.11 and EUR0.01 respectively, we can present the following investment outlook:
AnalysisGENOMIC VISION’s stock is currently trading well below its 52-week high price, suggesting that it has been oversold and may now be undervalued at its current value.
Note, however, that the stock’s current price is also significantly above its 52-week low; this indicates some volatility over the past year and may continue to do so going forward.
Recommendation Based on current information, now may be an ideal time to invest in GENOMIC VISION if you possess a high risk tolerance and believe strongly in its long-term prospects. As with any investment decision, however, thorough research should always precede making any definitive investments decisions; otherwise it may be prudent to wait for more favorable entry points should the stock continue experiencing volatility over the near term.
Technical Analysis
GENOMIC VISION’s stock price has recently experienced some upward momentum; however, this may not be sustainable over the long term.
Today’s reported volume of 192,604 is 86.07% lower than its average volume of 5,741,760 and could indicate that investors may not be as active trading the stock at this time.
By taking a closer look at GENOMIC VISION’s volatility, we can see that its current intraday variation average for the past week, month and quarter was positive 0.42%, negative 0.61% and 3.01%, respectively. Furthermore, its highest amplitude of average volatility during this time frame was 2.11% in each case (week, month and quarter respectively), suggesting that its price fluctuation has been relatively mild over time while experiencing occasional significant price shifts. These numbers demonstrate the stock’s recent success as an investment while experiencing significant fluctuations as well as some significant price movements in recent times.
Overall, GENOMIC VISION’s stock price appears to be trading above its 50-day moving average but still below its 200-day moving average. Given the low volume and volatility, investors must keep an eye on GENOMIC VISION’s performance as well as overall market conditions so as to make informed decisions when purchasing or selling.
Quarter Analysis
Based on the provided data, it appears that this stock has experienced year-on-year quarterly revenue growth of 3.8% year over year for twelve trailing months resulting in current annualized revenues of $1.48 Million. While this may signal expansion and possibly greater profitability for the company, other considerations such as expenses, profit margins and overall financial health must also be taken into account before making investment decisions. Comparing revenue growth against competitors or industries as a whole may also give insight into its market standing and potential for future expansion.
Equity Analysis
According to available data, GENOMIC VISION has experienced losses over the last year with an EPS figure of EUR-0.1, signalling losses that investors should avoid when selecting companies with positive earnings prospects.
Return on Equity (ROE) of the company was found to be negative -762.49% during its trailing 12-month period, which measures the profitability of a business relative to shareholder’s equity, suggesting it has not generated profits for shareholders.
Investors should proceed with caution when investing in GENOMIC VISION given its negative earnings and profitability metrics. Conduct a further analysis, such as reviewing financial statements or industry trends to ascertain if there may be positive factors that can offset such negative indicators.
More news about GENOMIC VISION (GV.PA).
